These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38506148)

  • 1. Safety and Duration of Effect of 40-Unit PrabotulinumtoxinA-xvfs for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients: A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Trial.
    Fagien S; Avelar RL; Cox SE; Joseph JH; Kaufman-Janette J; Marcus KA
    Aesthet Surg J; 2024 Aug; 44(9):987-1000. PubMed ID: 38506148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
    Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines.
    Gadarowski MB; Ghamrawi RI; Taylor SL; Feldman SR
    Ann Pharmacother; 2021 Mar; 55(3):354-361. PubMed ID: 32698599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA versus PrabotulinumtoxinA-xvfs: A Randomized, Triple-blind, Split-face Study on the Time to Onset, Rhytid Appearance, and Patient Satisfaction in Forehead and Glabellar Lines.
    Vasile G; Green C; Bhatti H; Ilyas M; Buckley C; Saleeby E; Weiss E
    J Clin Aesthet Dermatol; 2023 May; 16(5):47-49. PubMed ID: 37288279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study.
    Bertucci V; Humphrey S; Carruthers J; Solish N; Muhn C; Swift A; Rubio RG; Shears G; Rosen N
    Dermatol Surg; 2017 Dec; 43 Suppl 3():S262-S273. PubMed ID: 33065952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Lorenc ZP; Adelglass JM; Avelar RL; Baumann L; Beer KR; Cohen JL; Cox SE; Dayan SH; Dover JS; Downie JB; Draelos ZD; Goldman MP; Gross JE; Joseph JH; Kaufman-Janette J; Moy RL; Nestor M; Schlessinger J; Smith SR; Weiss RA
    Aesthet Surg J; 2021 Nov; 41(12):1423-1438. PubMed ID: 33944913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Kaufman-Janette J; Avelar RL; Biesman BS; Draelos ZD; Gross JE; Jones DH; Lupo MP; Maas CS; Schlessinger J; Shamban AT; Sundaram H; Weinkle SH; Young VL
    Aesthet Surg J; 2021 Nov; 41(12):1409-1422. PubMed ID: 33944905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies.
    Beer KR; Shamban AT; Avelar RL; Gross JE; Jonker A
    Dermatol Surg; 2019 Nov; 45(11):1381-1393. PubMed ID: 30893162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data.
    Solish N; Ascher B; Avelar RL; Bertucci V; Bodokh I; Carruthers J; Cartier H; Delmar H; Denfeld R; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Rzany BJ; Sattler G; Sebastian M; Swift A; Trévidic P
    Aesthet Surg J; 2022 Dec; 42(12):1460-1469. PubMed ID: 35922149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data.
    Cox SE; Ascher B; Avelar RL; Beer KR; Carruthers J; Cartier H; Fagien S; Solish N
    J Cosmet Dermatol; 2023 Jun; 22(6):1745-1756. PubMed ID: 37102990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data.
    Ogilvie P; Jones DH; Avelar RL; Jonker A; Monroe R; Carruthers J
    Dermatol Surg; 2022 Jun; 48(6):664-669. PubMed ID: 35616616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo.
    Carruthers J; Solish N; Humphrey S; Rosen N; Muhn C; Bertucci V; Swift A; Metelitsa A; Rubio RG; Waugh J; Quiring J; Shears G; Carruthers A
    Dermatol Surg; 2017 Nov; 43(11):1321-1331. PubMed ID: 28614091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data.
    Taylor SC; Grimes PE; Joseph JH; Jonker A; Avelar RL
    Dermatol Surg; 2021 Apr; 47(4):516-521. PubMed ID: 33165078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
    Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
    J Drugs Dermatol; 2020 Oct; 19(10):985-991. PubMed ID: 33026771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA.
    Dover JS; Solish N; Gross TM; Gallagher CJ; Brown J
    Dermatol Surg; 2023 Sep; 49(9):862-864. PubMed ID: 37384899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study.
    Rappl T; Parvizi D; Friedl H; Wiedner M; May S; Kranzelbinder B; Wurzer P; Hellbom B
    Clin Cosmet Investig Dermatol; 2013; 6():211-9. PubMed ID: 24098087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
    Li X; Sui C; Xia X; Chen X
    Aesthetic Plast Surg; 2023 Feb; 47(1):365-377. PubMed ID: 36097079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
    Carruthers JD; Fagien S; Joseph JH; Humphrey SD; Biesman BS; Gallagher CJ; Liu Y; Rubio RG; ;
    Plast Reconstr Surg; 2020 Jan; 145(1):45-58. PubMed ID: 31609882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.